home All News open_in_new Full Article

Cybin Completes Enrollment in Phase 2 Study Evaluating CYB004 for the Treatment of Generalized Anxiety Disorder

– The Phase 2 GAD study has enrolled 36 participants to evaluate the safety and efficacy of CYB004 at 12 weeks after first dose – – Reaffirms top-line data guidance for Q1 2026 – TORONTO — Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to advancing mental […]


today 6 d. ago attach_file Economics

attach_file Other
attach_file Politics
attach_file Economics
attach_file Other
attach_file Other
attach_file Culture
attach_file Society
attach_file Transport
attach_file Society
attach_file Culture
attach_file Economics
attach_file Other
attach_file Other
attach_file Other
attach_file Sport
attach_file Economics
attach_file Economics
attach_file Politics
attach_file Other
attach_file Science


ID: 2526913647
Add Watch Country

arrow_drop_down